Symbol Lookup

Monday August 31, 2015 5:42 PM ET. Data delayed 15 minutes.
18.96
-0.29 (-1.51%)
Bid/Lots
2.22/22
Ask/Lots
19.09/1
Open/Prev Close
19.16/19.25
Day Range
18.82-19.85
52-Week Range
7.53-23.61
Vol/Avg Daily Vol
654.8K/349.4K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide in Phase 2 Trial in Osteoarthritis
10:24AM ET on Thursday Aug 20, 2015 by PR Newswire
Companies Mentioned: CARA

Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the dosing of the first patients in a Phase 2 trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of osteoarthritis (OA). Cara's tablet formulation of CR845 utilizes Enteris' proprietary oral delivery technology.

Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the dosing of the first patients in a Phase 2 trial of an oral tablet formulation of its peripherally selective kappa opioid...

Aug 17, 2015

Cara Therapeutics Starts Phase 2 Trial of Oral CR845 For Treatment of Osteoarthritis
8:55AM ET on Monday Aug 17, 2015 by MT Newswires
Companies Mentioned: CARA
08:55 AM EDT, 08/17/2015 (MT Newswires) -- Cara Therapeutics (CARA) said it has dosed the first patients in a phase 2 trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of osteoarthritis....
08:55 AM EDT, 08/17/2015 (MT Newswires) -- Cara Therapeutics (CARA) said it has dosed the first patients in a phase 2 trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of osteoarthrit...
Cara Therapeutics Initiates Phase 2 Trial of Oral CR845 in Osteoarthritis
8:00AM ET on Monday Aug 17, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the dosing of the first patients in a Phase 2 trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of osteoarthritis (OA).

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the dosing o...

Aug 10, 2015

Cara Therapeutics Reports Second Quarter 2015 Financial Results
4:01PM ET on Monday Aug 10, 2015 by GlobeNewswire
Companies Mentioned: CARA

Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus

Completed successful public offering of common stock, raising net proceeds of $75.1 million

Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus

Completed successful public offering of common stock, raising net proceeds of $75.1 million

Aug 4, 2015

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:02PM ET on Tuesday Aug 04, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the closing of its underwritten public offering of 4,327,956 shares of its common stock at a public offering price of $18.60 per share, which included 564,516 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $80.5 million.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the clos...

← Newer12Older →

Peers Headlines

Today

The Myeloma Canada Research Network (MCRN) Moves Forward with Significant Funding Support from Karyopharm Therapeutics
less than 1 minute ago by CNW Group
Companies Mentioned: KPTI

Myeloma Canada is very pleased to announce the first major contribution by a pharmaceutical or biotechnology company supporting the formalization of the Myeloma Canada Research Network (MCRN). Karyopharm Therapeutics has made a significant dona...

Aug 12, 2015

Analyst Actions: Karyopharm Therapeutics Price Target Cut To $42 At MLV & Co., Reiterated Buy
7:20AM ET on Wednesday Aug 12, 2015 by MT Newswires
Companies Mentioned: KPTI
07:20 AM EDT, 08/12/2015 (MT Newswires) -- Karyopharm Therapeutics (KPTI) saw its price target lowered to $42 from $54 by MLV & Co. while the firm retained its buy rating on the stock. Price: 13.32, Change: +0.01, Percent Change: +0.08 ...

Aug 11, 2015

Analyst Actions: Neuroderm Price Target Raised To $24 At Oppenheimer, Reiterated Outperform
1:37PM ET on Tuesday Aug 11, 2015 by MT Newswires
Companies Mentioned: NDRM
01:37 PM EDT, 08/11/2015 (MT Newswires) -- Neuroderm (NDRM) saw its price target boosted to $24 from $19 by Oppenheimer while the firm retained its outperform rating on the stock. Price: 19.40, Change: +0.73, Percent Change: +3.91 ...
Sorrento Licensing CytoLumina's NanoVelcro Circulating Tumor Cell Profiling Assay
6:36AM ET on Tuesday Aug 11, 2015 by MT Newswires
Companies Mentioned: SRNE
06:36 AM EDT, 08/11/2015 (MT Newswires) -- Biopharmaceutical company Sorrento Therapeutics (SRNE) has entered into an agreement to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technolo...

Aug 10, 2015

Karyopharm Drops 38%; Reduces Dose for Cancer Drug in Phase 2 Trial After Sepsis Observed in Patients
2:38PM ET on Monday Aug 10, 2015 by MT Newswires
Companies Mentioned: KPTI
02:38 PM EDT, 08/10/2015 (MT Newswires) -- Karyopharm Therapeutics (KPTI) tumbled to a record low in Monday's afternoon trade after the clinical-stage pharmaceutical company said that it has lowered its dosage for oral selinexor in its Phase 2 c...
Sorrento Unit Buys Two Privately-Held Biotechnology Firms
7:35AM ET on Monday Aug 10, 2015 by MT Newswires
Companies Mentioned: SRNE
07:35 AM EDT, 08/10/2015 (MT Newswires) -- Sorrento Therapeutics (SRNE) Monday said its TNK Therapeutics subsidiary has acquired two privately-held biotechnology companies that own multiple pre-clinical and clinical stage chimeric antigen recepto...
Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
7:30AM ET on Monday Aug 10, 2015 by GlobeNewswire
Companies Mentioned: KPTI

- Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers -

- Provides Update to Certain Trials based on Expanding Clinical Experience -

Conference Call Scheduled for today at 8:30 a.m. ET

Sorrento's TNK Therapeutics Subsidiary Acquires Multiple Clinical Stage CAR-T Immunotherapy Programs
6:00AM ET on Monday Aug 10, 2015 by PR Newswire
Companies Mentioned: SRNE

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as wel...

Aug 6, 2015

Analyst Actions: NeuroDerm Price Target Raised To $27.5 At Roth Capital Partners, Reiterated Buy
1:46PM ET on Thursday Aug 06, 2015 by MT Newswires
Companies Mentioned: NDRM
01:46 PM EDT, 08/06/2015 (MT Newswires) -- NeuroDerm (NDRM) saw its price target boosted to $27.5 from $17.5 by Roth Capital Partners while the firm retained its buy rating on the stock. Price: 18.29, Change: -0.92, Percent Change: -4.79 ...

Aug 5, 2015

Geron Corporation Reports Second Quarter 2015 Financial Results
4:05PM ET on Wednesday Aug 05, 2015 by GlobeNewswire
Companies Mentioned: GERN

Geron Corporation (Nasdaq:GERN) today reported financial results for the second quarter ended June 30, 2015.

Second Quarter 2015 Results

For the second quarter of 2015, the company reported a net loss of $9.4 million, or $0.06 per...

← Newer12Older →